Masimo Co. (NASDAQ:MASI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages ...

NomoLine capnography and gas monitoring, and regional oximetry. Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and ...

Masimo is up 10.4% since the beginning of the year, and at $186.09 per share, has set a new 52-week high. Investors who bought $1,000 worth of Masimo’s shares 5 years ago would now be looking at ...

Learn more about whether Masimo Corporation or STERIS plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Masimo (MASI) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.25 per share a year ago. These figures ...

The protracted legal wrangling between Apple and health wearable company Masimo has resulted in a nominal win for the tech giant – but failed to achieve its objectives. Apple and Masimo have ...

Masimo (NASDAQ:MASI), a provider of noninvasive patient monitoring technology, released its fourth-quarter earnings for 2024, on Feb. 25, 2025. The results presented a mixed picture: strong ...

Masimo Corporation (NASDAQ ... CO-Oximetry and hemodynamics, capnography and gas and brain monitoring, all exceeding their respective growth targets. Within our capital equipment and other ...

key Masimo additions include Next Generation SedLine ® Brain Function Monitoring, O3 ® Regional Oximetry, and ISA™ Capnography with NomoLine ® sampling lines. Masimo’s family of continuous ...

Non-healthcare segments, while growing, were impacted by significant impairment charges. Masimo impressed with a robust earnings report driven by its healthcare segment, despite challenges from ...